Eli Lilly Announces Pivotal Phase 3 Results for Retatrutide

Eli Lilly and Company has announced top-line results from TRIUMPH-1, the first pivotal Phase 3 trial of retatrutide — a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors — in adults with obesity. The company stated that retatrutide delivered 'powerful weight loss' in the trial, marking a significant milestone for the next generation of incretin-based therapies.\n Retatrutide is distinct from currently approved GLP-1 agonists such as semaglutide and the dual-agonist tirzepatide (which targets GLP-1 and GIP) by virtue of its triple mechanism: it simultaneously activates three incretin hormone pathways. This additional glucagon receptor activity is thought to increase energy expenditure through hepatic gluconeogenesis modulation and thermogenesis, complementing the appetite-suppressing and insulin-sensitising effects of GLP-1 and GIP activation.

Building on Phase 2 Promise

The Phase 3 readout follows retatrutide's Phase 2 trial, published in The New England Journal of Medicine in 2023, which demonstrated a mean weight reduction of up to 24.2% at 48 weeks at the highest dose (12 mg). That Phase 2 result was among the highest weight losses reported for any pharmacological agent at the time, and it helped establish retatrutide as one of the most closely watched compounds in the obesity pipeline.

In the Phase 2 study, retatrutide also showed improvements in glycaemic control and cardiometabolic markers, including reductions in waist circumference, blood pressure, and triglycerides. The drug's safety profile in Phase 2 was broadly consistent with the incretin class, with gastrointestinal adverse events (nausea, diarrhoea, vomiting) being the most common, typically mild to moderate, and decreasing over time.

What the Phase 3 Results Mean

The TRIUMPH-1 trial enrolled adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related comorbidities. While detailed data — including exact weight loss percentages, dose-response, and full safety results — are expected to be presented at an upcoming medical congress and published in a peer-reviewed journal, the announcement confirms that retatrutide's efficacy has been replicated in a larger, pivotal setting.

This is notable for several reasons:

  • Triple agonism validated: The result provides the first Phase 3 confirmation that targeting three incretin receptors simultaneously can produce clinically meaningful weight loss, potentially surpassing dual-agonist approaches.
  • Pipeline competition intensifies: Retatrutide enters an increasingly competitive landscape alongside tirzepatide (already approved for obesity as Mounjaro/Zepbound), semaglutide (Wegovy), and emerging agents including orforglipron (oral GLP-1), cagrisema, and survodutide.
  • Safety in focus: As a triple agonist with glucagon receptor activity, retatrutide's long-term safety profile will be closely scrutinised, particularly regarding heart rate elevations observed in Phase 2.

UK Context

Retatrutide is not currently licensed by the MHRA or EMA for any indication. As an investigational compound, it remains available only through clinical trial participation. Eli Lilly's Phase 3 programme (the TRIUMPH series) includes multiple trials evaluating retatrutide in obesity, type 2 diabetes, and obstructive sleep apnoea.

For researchers, retatrutide represents a significant pharmacological proof-of-concept for multi-receptor agonism. Its development trajectory provides a framework for understanding how next-generation incretin therapeutics may be designed — combining complementary receptor activities to achieve greater efficacy than single- or dual-pathway approaches.

Looking Ahead

Full TRIUMPH-1 results, including primary and key secondary endpoint data, are anticipated at a major medical congress in 2025, with peer-reviewed publication to follow. Additional Phase 3 trials in the TRIUMPH programme — including studies in type 2 diabetes (TRIUMPH-2) and obstructive sleep apnoea (TRIUMPH-3) — are ongoing.

If the detailed data confirm the magnitude of weight loss suggested by the Phase 2 study and the company's characterisation, retatrutide could represent a meaningful step-change in obesity pharmacotherapy. Regulatory submissions to the FDA, EMA, and MHRA would follow upon completion of the Phase 3 programme.

This article is for research and educational purposes only. Retatrutide is an investigational compound not approved for human use outside of clinical trials. Nothing in this article constitutes medical advice.

Related: Read our full retatrutide compound profile for mechanism of action, research evidence, and UK legal status.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.